1 / 14

Ying G-S, Maguire MG , Jaffe GJ, Grunwald JE, Toth C, Daniel E,

Baseline Predictors for One Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration. Ying G-S, Maguire MG , Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF for the CATT Research Group

takara
Download Presentation

Ying G-S, Maguire MG , Jaffe GJ, Grunwald JE, Toth C, Daniel E,

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Baseline Predictors for One Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration Ying G-S, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF for the CATT Research Group Available through http://www.med.upenn.edu/cpob/publications_main.shtml Supported by Cooperative Agreements from the National Eye Institute, National Institutes of Health, DHHS 1

  2. Age Mean VA (SE) Mean VA Change (SE) 67 66 72 69 % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

  3. Baseline VA in Study Eye Mean VA Change (SE) Mean VA (SE) 67 66 72 69 20/X % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

  4. Baseline VA in Fellow Eye % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

  5. Baseline IOP Mean VA (SE) Mean VA Change (SE) 67 66 72 69 Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

  6. Baseline CNV Area Mean VA Change (SE) Mean VA (SE) 67 66 72 69 % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

  7. Lesion Type Mean VA (SE) Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

  8. RAP Lesion % of ≥3-lines Gain Mean VA Change (SE) 67 66 72 69 Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

  9. Baseline Geographic Atrophy Mean VA (SE) Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

  10. Baseline Foveal Thickness % of ≥3-lines Gain Mean VA (SE) 67 66 72 69 Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

  11. Baseline RPE Elevation Mean VA (SE) Mean VA Change (SE) 67 66 72 69 % of ≥3-lines Gain Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

  12. Conclusions Baseline VAVA at 1 YearChange in VA at 1 Year Mean (SE) P-value Mean(SE) P-value <0.0001 <0.0001 20/25 - 20/40 76.4 (0.8) 3.3 (0.7) 20/50 - 20/80 69.2 (0.7) 8.4 (0.7) 20/100 – 20/160 59.1 (1.0) 12.0 (1.0) 20/200 - 20/320 41.3 (1.8) 7.6 (1.7) Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129 Early treatment before VA is profoundly affected will achieve the best VA outcomes

  13. Conclusions Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129

  14. Conclusions Ying et al. Baseline Predictors for 1 yr. visual outcomes with ranibizumab or bevacizumab for neovascular AMD Ophthalmology 2013;120:122-129 Baseline predictors of one year VA outcomes are:

More Related